Scholars@Duke publication: Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma

Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma

Publication , Conference

Hanks, BA

Duke Scholars

Author Brent A. Hanks Medicine, Medical Oncology

Location

Pasadena, California

Conference Name

2nd Annual Summit on Melanoma

Citation

APA

Chicago

ICMJE

MLA

NLM

Hanks, B. A. (n.d.). Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma. Presented at the 2nd Annual Summit on Melanoma, Pasadena, California.

Hanks, B. A. “Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma,” n.d.

Hanks BA. Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma. In.

Hanks, B. A. Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma.

Hanks BA. Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma.

Location

Pasadena, California

Conference Name

2nd Annual Summit on Melanoma